Cost-Effectiveness of Once-Weekly Insulin Icodec versus Daily Basal Insulins in Chinese Adults with T2DM: A Treatment-Background Stratified Analysis
Insulin icodec offers cost-saving potential versus degludec in insulin-naïve T2DM patients. For basal and basal-bolus-treated patients, the clinical use of icodec needs to be critically evaluated for cost burden, and it is recommended that it be used preferentially in patients who are sensitive to the frequency of injections.
Authors
- Zeyu Xie (ORCID: https://orcid.org/0000-0002-1609-4377)
- Zhuoru Liang
- Yuanyun Xie
- Weishang Deng (ORCID: https://orcid.org/0000-0003-1131-6417)
- Weiling Cao (ORCID: https://orcid.org/0000-0002-1212-0320)
- Jisheng Chen (ORCID: https://orcid.org/0000-0003-3514-9086)
Institutions
- Chinese University of Hong Kong (HK)
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
- Shenzhen Luohu People's Hospital (CN)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/ceor.s539841
- Citations
- 2
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- University of Oxford
- Sanming Project of Medicine in Shenzhen